论文信息 - Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. - 字舞流文

Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.

Circulation. 2018;138:1904–1907. DOI: 10.1161/CIRCULATIONAHA.118.035759 1904

B. Zinman | C. Wanner | D. Fitchett | S. Inzucchi | J. George | M. Kosiborod | S. Kaspers | U. Hehnke

[1] B. Zinman,et al. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial , 2017, Diabetes Care.

[2] M. Fischereder,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[3] B. Zinman,et al. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial , 2016, European heart journal.

[4] Vilmundur Gudnason,et al. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death , 2011 .

[5] Thomas E. Moritz,et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes , 2009, Diabetologia.